share_log

Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years

Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years

武田的遗传性血管水肿治疗可防止12岁以下儿童发作
Benzinga Real-time News ·  2022/07/01 10:30
  • Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
  • The data demonstrated positive results of Takhzyro (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients.
  • HAE attacks, which can involve serious and severely debilitating swelling in the abdomen, face, feet, genitals, hands, and throat, may occur very early in childhood. 
  • Takhzyro reduced the rate of HAE attacks in children by a mean of 94.8% compared to baseline, from 1.84 attacks per month to 0.08 attacks during treatment.
  • Most patients (76.2%) were attack-free during the 52-week treatment period, with an average of 99.5% attack-free days.
  • No deaths or serious treatment-emergent adverse events (TEAEs) were reported during the study, and no patients withdrew from the study due to TEAEs.
  • Price Action: TAK shares are down 0.64% at $13.95 during the market session on the last check Friday.
  • 武田药品工业株式会社(纽约证券交易所市场代码：Tak) 在2022年欧洲过敏和临床免疫学混合大会上公布的第三阶段春季研究的最新数据。
  • 数据显示，Takhzyro(Lanadelumab)在预防遗传性血管性水肿(HAE)发作方面取得了积极的结果，患者2至
  • HAE发作，包括腹部、面部、脚、生殖器、手和喉咙的严重和严重虚弱的肿胀，可能发生在很小的儿童时期。
  • 与基线相比，Takhzyro将儿童HAE发作的发生率平均降低了94.8%，从每月1.84次发作减少到治疗期间的0.08次发作。
  • 大多数患者(76.2%)在52周的治疗期间没有发作，平均99.5%的无发作天数。
  • 在研究期间，没有死亡或严重的紧急治疗不良事件(TEAE)的报告，也没有患者因TEAE而退出研究。
  • 价格行动：在周五尾盘交易时段，德意志银行股价下跌0.64%，至13.95美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发